PAP
RARE icon

Persistent Asset Partners’s Ultragenyx Pharmaceutical RARE Stock Holding History

Persistent Asset Partners’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-320
Closed -$215K – 431
2025
Q3 		$215K Sell
320
-27,712
-99% -$831K 0.15% 129
2025
Q2 		$392K Buy
28,032
+27,712
+8,660% +$999K 0.29% 89
2025
Q1 		$258K Hold
320
– – 0.22% 88
2024
Q4 		$174K Buy
+320
New +$15.9K 0.14% 91

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Persistent Asset Partners's RARE Position: Q2 2026 in Review

Persistent Asset Partners sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2026, closing a stake of 8,884 shares — an estimated $186K sold.

Persistent Asset Partners first reported a position in RARE in Q2 2025 and held it in 4 quarters. The position peaked at $452K in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Persistent Asset Partners reported no remaining Ultragenyx Pharmaceutical position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 8,884 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $186K.
  • Persistent Asset Partners first reported a position in Ultragenyx Pharmaceutical in Q2 2025 and held it in 4 quarters.
  • Persistent Asset Partners's Ultragenyx Pharmaceutical position peaked at $452K in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.